Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

Bristol-Myers Squibb (BMY) stock shows potential for growth with recent FDA approval and strong oncology portfolio, but faces ...